Clinical trial NCT04121949: Cost-effectiveness and Safety of the CADScorSystem in Patients With Symptoms Suggestive of Stable Coronary Artery Disease.
Official title: A Prospective, Randomized, Controlled, Parallel-group, Multicentre Trial to Examine the Cost-effectiveness and Safety of Adding the CADScorSystem as a Rule-out Test in Patients Referred With Symptoms Suggestive of Stable Coronary Artery Disease.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Angina, Stable
Keywords: coronary artery disease
diagnostic strategies
Lead sponsor: Bispebjerg Hospital
Sponsor class: OTHER
Collaborators: name: Region Hovedstadens Apotek
name: Larix A/S
name: Acarix
name: Kai Hansen Foundation
name: Kai Houmann Nielsens Fond
First posted: 2019-10-10
Enrollment: 2016
Sex: ALL
Minimum age (years): 30
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This study is designed as a randomized, controlled, multicentre, superiority trial with two parallel groups including patients with symptoms suggestive of stable CAD at a low-to-intermediate likelihood of obstructive CAD (pre-test probability of 0-85%). Subjects will be randomized 1:1 to either (1) standard diagnostic strategy according to current guidelines, i.e. DF-score stratification followed by NIT, if indicated, or (2) DF-score plus CAD-score stratification followed by NIT, if indicated.
Primary purpose: DIAGNOSTIC

Brief summary: This study evaluates the addition of the CADScorSystem to a standard Diamond-Forrester score guided rule-out strategy in ambulatory patients referred with symptoms suggestive of stable coronary artery disease. Half of the patients will undergo stratification using a Diamond-Forrester score only, while the other half will undergo stratification using a Diamond-Forrester score and a CAD-score. The study hypothesis is that the addition of a CAD-score will reduce unnecessary testing without compromising patient safety.

Detailed description: Purpose and Rationale for the Study:

The declining incidence of obstructive CAD and a good prognosis for patients with stable angina challenges the resource demanding approach recommended in current guidelines. The CADScor®System may be an efficient, fast and low-cost diagnostic tool with a high rule-out efficiency. The current study aims to investigate if the CADScor®System can be added as a rule-out test in patients referred with suspected stable CAD to reduce unnecessary testing

Study Hypothesis:

A Diamond-Forrester score plus CAD-score guided rule-out strategy is superior to a Diamond-Forrester score guided strategy alone in reducing diagnostic procedures and non-inferior in terms of safety outcomes in patients with symptoms suggestive of stable coronary artery disease.

Study Setting:

This study will enrol patients without known CAD who are referred with symptoms suggestive for stable CAD for outpatient evaluation at the participating sites. All patients will be symptomatic and require evaluation for suspected CAD. Thus, whether or not the patient chooses to participate in the study, the patient will undergo evaluation for suspected CAD. All the standard NIT modalities and ICA in the study are clinically well established and performed routinely and safely. Experimental testing involves the CADScor®System, for ruling out CAD before any NIT in the intervention group.

End of Study:

The study will end when all the following have occurred: (1) at least 2000 patients have been randomized, and (2) 12±1 months (1 year) have elapsed since the last patient was randomized.

Extended Follow-up after Study Termination:

Follow-up might be performed for up to 10 years after randomization. Follow-up information will be extracted from national registers, including information on cardiovascular events and treatments, hospitalizations and ambulatory visits due to cardiovascular events, and causes of death.

Statistical methods:

A detailed description of the planned statistical analyses will be documented in a separate statistical report and analysis plan (SAP), which will be completed before data base lock.

Sample size considerations:

A reduction of 15% or more in the primary endpoint is regarded as clinically significant. Assuming an alpha significance level of 0.05, a statistical power of 80% and an expected number of NIT/ICA of 0.94 per patient in the standard care group, a sample size of 314 patients in each arm is needed to ascertain superiority of the intervention.

A sample size of 1914 provides 90% power for testing non-inferiority in terms of MACE between the two testing strategies, at an alpha significance level of 0.05.

We choose to include 2000 patients, i.e. 1000 patients in each group, allowing for a 4% loss to follow-up and drop out and providing power for the primary endpoint and the secondary MACE non-inferiority endpoint.

Statistical analysis:

The full analysis set (FAS) will include all randomized patients in whom written informed consent was obtained and in accordance with the intention-to-treat principle all patients will be analysed according to the allocated treatment group.

The per-protocol set (PPS) will include only those patients from the FAS who did not have one of the following major protocol violations: inclusion criteria not met, exclusion criteria met, no DF-score calculation, or no CAD-score measurement (intervention group only). Patients who did not receive the randomly allocated CAD-score measurement will be included and analysed in the control group (per protocol analysis).

Eligibility criteria: Inclusion Criteria:

1. Have signed the informed consent form.
2. Males and females, aged 30 years or above.
3. Be able and willing to comply with the clinical investigational plan.
4. Symptoms suggestive of stable coronary artery disease.
5. No history of coronary artery disease (prior myocardial infarction, percutaneous coronary intervention or coronary artery bypass graft).

Exclusion Criteria:

1. Diamond-Forrester score \>85%.
2. Prior non-invasive testing for stable CAD or invasive coronary angiography within 6 months of randomization.
3. Implanted donor heart, mechanical heart, mechanical heart pump.
4. Pacemaker or Cardioverter Defibrillator (ICD).
5. Implanted electronic equipment in the area above and around the heart.
6. Significant operation scars, abnormal body shape, fragile or compromised skin in the fourth left intercostal space recording area.
7. Receiving same day treatment with nitro-glycerine on the day of randomization.
8. Pregnancy.

The exclusion criteria '1. Diamond-Forrester score \>85%' was removed after updating the study according to the 2019 ESC guidelines on chronic coronary syndrome. According to these current guidelines, no patients should be referred to invasive diagnostic test based on their PTP alone, and therefore is this exclusion criteria is no longer relevant.

Primary outcomes:
measure: Cumulative number of non-invasive and invasive diagnostic procedures
timeFrame: 1 year
Secondary outcomes:
measure: Incidence of Major adverse cardiac events (MACE)
timeFrame: 1 year
Other outcomes:
measure: Change in chest pain
timeFrame: 3 months and 1 year
measure: Change in quality of life
timeFrame: 3 months and 1 year
measure: First non-invasive tests
timeFrame: 1 year
measure: Downstream tests
timeFrame: 1 year
measure: Invasive coronary angiographies (ICA)
timeFrame: 1 year
measure: Negative invasive coronary angiographies
timeFrame: 1 year
measure: Repeat referrals
timeFrame: 1 year
measure: Time to rule-out CAD
timeFrame: 1 year
measure: Time to diagnosis of CAD
timeFrame: 1 year
measure: Change in lifestyle measures
timeFrame: 3 months and 1 year
measure: Optimal medical treatment
timeFrame: 1 year
measure: Incidence of individual components of MACE
timeFrame: 1 year
measure: Cumulative contrast dose
timeFrame: 1 year
measure: Cumulative radiation dose
timeFrame: 1 year
measure: Bleedings requiring hospitalization
timeFrame: 1 year
measure: Adverse events
timeFrame: 1 year
Locations:
city: Copenhagen S
country: Denmark
facility: Amager Hospital
city: Herlev
country: Denmark
facility: University Hospital Herlev and Gentofte
city: Hillerød
country: Denmark
facility: University Hospital Nordsjaelland
city: Hvidovre
country: Denmark
facility: University Hospital Hvidovre
city: København NV
country: Denmark
facility: University Hospital Bispebjerg and Frederiksberg
city: Lund
country: Sweden
facility: Skane University Hospital
Study officials:
affiliation: Bispebjerg og Frederiksberg Hospitaler
name: Eva Prescott, DMSc.
role: PRINCIPAL_INVESTIGATOR
affiliation: Bispebjerg og Frederiksberg Hospitaler
name: Søren Galatius, DMSc.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bjerking LH, Hansen KW, Biering-Sorensen T, Bronnum-Schou J, Engblom H, Erlinge D, Haahr-Pedersen SA, Heitmann M, Hove JD, Jensen MT, Kruse M, Rader S, Strange S, Galatius S, Prescott EIB. Cost-effectiveness of adding a non-invasive acoustic rule-out test in the evaluation of patients with symptoms suggestive of coronary artery disease: rationale and design of the prospective, randomised, controlled, parallel-group multicenter FILTER-SCAD trial. BMJ Open. 2021 Aug 23;11(8):e049380. doi: 10.1136/bmjopen-2021-049380.